Seock-Ah Im Selected Research

HM781-36B

12/2020	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
1/2019	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
12/2018	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
7/2018	Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
3/2012	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
3/2011	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seock-Ah Im Research Topics

Disease

235	Breast Neoplasms (Breast Cancer) 05/2024 - 12/2004
183	Neoplasms (Cancer) 05/2024 - 12/2004
57	Stomach Neoplasms (Stomach Cancer) 01/2023 - 11/2004
36	Neoplasm Metastasis (Metastasis) 01/2023 - 06/2005
35	Triple Negative Breast Neoplasms 05/2024 - 11/2007
26	Neutropenia 01/2024 - 12/2012
25	Disease Progression 12/2023 - 01/2012
16	Colorectal Neoplasms (Colorectal Cancer) 12/2016 - 06/2005
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2014 - 01/2005
14	Adenocarcinoma 01/2023 - 11/2004
11	Nausea 12/2023 - 02/2009
11	Vomiting 12/2023 - 12/2004
10	Biliary Tract Neoplasms (Biliary Tract Cancer) 10/2017 - 12/2008
9	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 10/2011
9	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 12/2005
8	Pathologic Complete Response 11/2023 - 12/2012
8	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2023 - 09/2011
7	Febrile Neutropenia 01/2021 - 01/2012
7	Lymphatic Metastasis 08/2016 - 06/2005
6	Fatigue 02/2024 - 10/2016
6	Leukopenia 01/2019 - 11/2016
5	Thrombocytopenia (Thrombopenia) 01/2024 - 07/2016
5	Pneumonia (Pneumonitis) 01/2023 - 12/2013
5	Carcinoma (Carcinomatosis) 01/2022 - 11/2004
5	Brain Neoplasms (Brain Tumor) 12/2021 - 01/2017
5	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2017 - 01/2014
5	Colonic Neoplasms (Colon Cancer) 05/2013 - 10/2011
4	Anemia 01/2024 - 11/2016
4	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2022

Drug/Important Bio-Agent (IBA)

72	Hormones (Hormone)IBA 05/2024 - 02/2010
46	ErbB Receptors (EGF Receptor)IBA 02/2024 - 01/2005
45	Trastuzumab (Herceptin)FDA Link 12/2023 - 01/2008
37	human ERBB2 proteinIBA 03/2024 - 10/2008
31	Biomarkers (Surrogate Marker)IBA 05/2024 - 07/2011
30	Estrogen ReceptorsIBA 01/2024 - 10/2008
28	Fluorouracil (Carac)FDA LinkGeneric 10/2021 - 06/2005
27	Docetaxel (Taxotere)FDA Link 12/2023 - 11/2007
27	taxaneIBA 04/2023 - 06/2008
26	Proteins (Proteins, Gene)FDA Link 10/2023 - 06/2005
25	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 11/2004
22	palbociclibIBA 01/2024 - 04/2016
21	AnthracyclinesIBA 11/2023 - 08/2005
21	Gemcitabine FDA Link 01/2022 - 06/2006
17	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 07/2006
17	Capecitabine (Xeloda)FDA Link 04/2022 - 01/2011
17	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 11/2004
15	olaparibIBA 02/2024 - 06/2013
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2023 - 09/2005
14	Oxaliplatin (Eloxatin)FDA LinkGeneric 04/2023 - 05/2008
14	Fulvestrant (Faslodex)FDA Link 01/2022 - 04/2016
13	pertuzumabIBA 12/2023 - 01/2012
11	Tamoxifen FDA LinkGeneric 11/2023 - 07/2012
11	PlatinumIBA 11/2023 - 07/2006
11	Lapatinib (GW572016)FDA Link 01/2021 - 03/2008
10	Aromatase InhibitorsIBA 03/2024 - 07/2012
10	ribociclibIBA 03/2024 - 01/2018
10	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2005
9	pembrolizumabIBA 05/2024 - 01/2018
9	Tyrosine Kinase InhibitorsIBA 07/2018 - 03/2008
9	Gefitinib (Iressa)FDA Link 02/2012 - 01/2005
8	Letrozole (Femara)FDA LinkGeneric 03/2024 - 01/2014
8	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2023 - 06/2013
8	Epidermal Growth Factor (EGF)IBA 10/2023 - 11/2006
8	Cyclin-Dependent Kinase 4IBA 10/2023 - 01/2017
8	Leucovorin (Folinic Acid)FDA Link 07/2016 - 05/2008
7	Taxoids (Taxanes)IBA 11/2023 - 08/2005
7	Progesterone Receptors (Progesterone Receptor)IBA 10/2023 - 10/2008
7	Ado-Trastuzumab EmtansineIBA 01/2023 - 12/2018
7	Imatinib Mesylate (Gleevec)FDA Link 01/2023 - 09/2011
7	Phenobarbital (Luminal)FDA Link 05/2019 - 01/2013
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 09/2008
6	B7-H1 AntigenIBA 05/2024 - 11/2016
6	eribulin FDA Link 12/2023 - 04/2017
6	Vinorelbine (Navelbine)FDA LinkGeneric 11/2023 - 06/2008
6	Bevacizumab (Avastin)FDA Link 11/2023 - 12/2012
6	trastuzumab deruxtecanIBA 01/2023 - 01/2020
6	exemestane (Aromasin)FDA Link 07/2021 - 03/2013
6	HM781-36BIBA 12/2020 - 03/2011
6	Cetuximab (Erbitux)FDA Link 01/2013 - 03/2008
5	LigandsIBA 05/2024 - 01/2016
5	CytokinesIBA 01/2023 - 12/2013
5	Monoclonal AntibodiesIBA 01/2022 - 11/2005
5	Gonadotropin-Releasing Hormone (GnRH)FDA Link 11/2020 - 01/2017
5	thiamine triphosphorate (TTP)IBA 11/2018 - 08/2010
5	etirinotecan pegolIBA 01/2018 - 11/2015
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018 - 05/2011
5	Sunitinib (Sutent)FDA Link 04/2017 - 07/2011
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 09/2011
4	RNA (Ribonucleic Acid)IBA 01/2023 - 10/2007
4	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 12/2020
4	130-nm albumin-bound paclitaxelIBA 04/2022 - 09/2017

Therapy/Procedure

150	Drug Therapy (Chemotherapy) 05/2024 - 11/2004
118	Therapeutics 05/2024 - 12/2005
48	Neoadjuvant Therapy 01/2024 - 11/2007
29	Adjuvant Chemotherapy 02/2024 - 12/2004
24	Radiotherapy 02/2024 - 07/2006
13	Combination Drug Therapy (Combination Chemotherapy) 11/2017 - 11/2004
12	Adjuvant Chemoradiotherapy 04/2017 - 02/2009
8	Chemoradiotherapy 10/2021 - 02/2009
7	Segmental Mastectomy (Lumpectomy) 12/2016 - 06/2005